Testing version — LOERadar is in active testing. Features and data may change.
ZOFRAN (ONDANSETRON HYDROCHLORIDE) | LOERadar
ZOFRAN
NDA
ONDANSETRON HYDROCHLORIDE | N020007 | SANDOZ INC
2 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
#001 — EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
INJECTABLE;INJECTION | Approved: Jan 4, 1991
No patent or exclusivity listings for this strength.
#003 — EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**